The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies.
Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in people with pyruvate kinase deficiency. Hemolysis refers to the destruction of red blood cells.
-copy-dd1f2bf0.jpeg?w=600)
